BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30027525)

  • 1. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.
    Durbas M; Pabisz P; Wawak K; Wiśniewska A; Boratyn E; Nowak I; Horwacik I; Woźnicka O; Rokita H
    Apoptosis; 2018 Oct; 23(9-10):492-511. PubMed ID: 30027525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis is responsible for the cytotoxic effects of anti-GD2 ganglioside antibodies and aurora A kinase inhibitors on human neuroblastoma cells.
    Durbas M; Rokita H; Horwacik I; Wiśniewska A; Nowak I
    Acta Biochim Pol; 2022 Jul; 69(3):485-494. PubMed ID: 35810485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of the PHLDA1 gene in IMR-32 neuroblastoma cells increases levels of Aurora A, TRKB and affects proteins involved in apoptosis and autophagy pathways.
    Durbas M; Horwacik I; Boratyn E; Rokita H
    Int J Oncol; 2016 Aug; 49(2):823-37. PubMed ID: 27278006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
    Horwacik I; Rokita H
    Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Sawicka A; Węgrzyn P; Krzanik S; Górka A; Drożniak J; Augustyniak E; Kowalczyk A; Rokita H
    Acta Biochim Pol; 2015; 62(3):423-33. PubMed ID: 26284262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.
    Horwacik I; Kurciński M; Bzowska M; Kowalczyk AK; Czaplicki D; Koliński A; Rokita H
    Int J Mol Med; 2011 Jul; 28(1):47-57. PubMed ID: 21455557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
    Liu B; Wu Y; Zhou Y; Peng D
    PLoS One; 2014; 9(4):e93576. PubMed ID: 24727660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
    Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
    Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
    Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
    Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.
    Corallo D; Pastorino F; Pantile M; Mariotto E; Caicci F; Viola G; Ponzoni M; Tonini GP; Aveic S
    J Exp Clin Cancer Res; 2020 Sep; 39(1):195. PubMed ID: 32962733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Caspases participarion in the cell death induced by GD2-specific monoclonal antibody].
    Vishniakova PA; Doronin II; Holodenko IV; Riazantsev DIu; Molotkovskaia IM; Holodenko RV
    Bioorg Khim; 2014; 40(3):305-14. PubMed ID: 25898737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
    Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D
    J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
    Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
    PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.
    Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL
    Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
    Mujoo K; Reisfeld RA; Cheung L; Rosenblum MG
    Cancer Immunol Immunother; 1991; 34(3):198-204. PubMed ID: 1756537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.